3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
39
Colonic Neoplasms
10
Neoplasms
8
Stomach Neoplasms
7
Neoplasm Metastasis
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Gastrointestinal Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Unresectable Metastatic Colorectal Cancer
2
Liver Neoplasms
2
Gastrointestinal Diseases
2
Gallbladder Neoplasms
2
Digestive System Neoplasms
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Recurrence, Local
1
Melanoma
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Interventions
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
liposomal doxorubicin
2
durvalumab
2
Nivolumab
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
tremelimumab
1
tivozanib
1
ricolinostat
1
pomalidomide
1
nilotinib
1
capivasertib
1
Zoledronic Acid
1
Vitamin D
1
Taxes
1
Oxaliplatin
1
Leucovorin
1
Lenalidomide
1
Fulvestrant
1
Folfox protocol
1
Fluorouracil
1
Cyclophosphamide
1
Clinical Trials, Phase II as Topic
1
Clinical Trials, Phase I as Topic
1
Cisplatin
1
Calcium
1
Bortezomib
1
AZD 6244
1
10-propargyl-10-deazaaminopterin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Disease Progression
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts